Researchers have revealed that patients who undergo a liver transplant are at increased risk (they put as 3 times more likely) of developing cancer than the general population.
Transplantation, and subsequent immunosuppression which keeps rejection at bay, have long been associated with increased cancer risk.
The research team led by Helena Isoniemi of Finland analysed cancer risk pattern in Finnish liver transplant patients from Helsinki University Central between 1982 and 2005.
Among the 540 liver transplant recipients, they found a total of 39 post-transplant de novo cancers in 36 patients.
The overall standardized incidence ratio (SIR) compared to the general population was 2.59. Non-Hodgkin lymphoma, non-melanoma skin cancer and basal cell carcinoma had significantly elevated SIRs.
"The most common cancer types in our cohort were lymphoma and skin cancer," the authors report.
"Non-Hodgkin lymphoma, which included four cases of post-transplant lymphoproliverative disorder, occurred more frequently in males, in patients transplanted at a younger age and soon after transplantation."
By contrast, non-melanoma skin cancer was more common among older patients and those who had antibody induction therapy.
In an accompanying editorial by Ashok Kumar Jain of the University of Rochester reviewed the Aberg et al findings alongside the rest of the literature, looking closely at patient age and duration of follow-up.
Aberg and colleagues "show that the cumulative incidence of de novo cancers increased at 1, 5, 10 and 20 years of follow up from 3 percent, 5 percent, 13 percent and 16 percent respectively," Jain writes.